Elizabeth Mora
About Elizabeth Mora
Elizabeth Mora (age 64) is an independent director of Limoneira (LMNR) since 2021. She is a seasoned financial expert and operations executive with 30+ years across accounting, higher education, and research; she is a CPA, holds a BA from UC Berkeley and an MBA from Simmons College, and currently chairs LMNR’s Compensation and Nominating & Corporate Governance Committees . She is independent under NASDAQ rules and brings a sustainability focus to the board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Charles Stark Draper Laboratory | Chief Administrative Officer; VP Finance, Administration & Treasurer | 2008–2020 | Senior financial leadership and operations |
| Harvard University | CFO & VP Finance; Associate VP Research Administration; Director, Office for Sponsored Research | 1997–2008 | Led financial and research administration functions |
| PricewaterhouseCoopers (Coopers & Lybrand) | Senior Manager; Audit Senior/Manager | 1989–1997 | Audit and accounting leadership |
External Roles
| Company | Role | Tenure | Committees/Notes |
|---|---|---|---|
| Inogen (INGN) | Chairperson of the Board; member of Compensation and Nominating & Governance; former Compliance Chair | Director since May 2021 | Board chair; committee leadership |
| MKS Instruments (MKSI) | Director; Audit Committee Chair | Current | Audit Committee Chair; authored Audit Committee Report |
| GCP Applied Technologies (GCP) | Director | 2016–2020 | Prior public board service |
| Everest Consolidator Acquisition Corp (MNTN) | Director | 2020–2024 | SPAC board service |
| Nuburu (BURU) | Director; Audit Committee Chair | 2023–2025 | Audit Chair, financial expert designation |
| Everest Consolidator LLC | Director | Current | Private company board |
| Cambridge Bancorp | Advisory Board Member | Since 2017 | Advisory role |
Board Governance
- Committee assignments (LMNR): Mora chairs Compensation; chairs Nominating & Corporate Governance; not a member of the Audit & Finance Committee .
- Independence: Board determined Mora is independent (NASDAQ definition); all standing committee members are independent .
- Attendance: Board met 9 times in FY 2024 (including 4 special); six of seven directors attended the 2024 Annual Meeting .
- Committee engagement: Compensation Committee met 7 times in FY 2024 with 95% attendance (Mora was Chair); Audit Committee met 4 times with 100% attendance .
- Executive sessions: Non-management director executive sessions held at each regular Board and committee meeting .
Fixed Compensation
| Company | Year | Cash Retainer/Fees ($) | Committee Chair Fees ($) | Notes |
|---|---|---|---|---|
| Limoneira (LMNR) | FY 2024 | 90,000 | Included in cash; not itemized | Board approved increases to annual retainer and equity awards effective Nov 1, 2024 to align with market (Pearl Meyer review) |
| MKS Instruments (MKSI) | 2024 | 120,000 | Included; serves as Audit Chair | Total cash fees as reported |
| Inogen (INGN) | 2023 | 135,000 | Included; Board Chair | Chair role disclosed; fees aggregate in cash compensation |
Performance Compensation
| Company | Year | Equity Type | Grant Date | Grant Value ($) | Shares/Units (#) | Vesting | Performance Metrics |
|---|---|---|---|---|---|---|---|
| Limoneira (LMNR) | FY 2024 | Restricted Stock | Mar 26, 2024 | 85,000 | 4,413 equivalent shares (priced at $19.26) | One-year vest on Mar 26, 2025; voting/dividend rights during vest | None; LMNR does not issue options to directors; non-management directors have no option awards |
| MKS Instruments (MKSI) | 2024 | RSUs | 2024 | 198,621 | Outstanding RSUs for non-employee directors 1,622 each (as of Dec 31, 2024) | Per MKSI director program | Not specified for directors |
| Inogen (INGN) | 2023 | RSUs | 2023 | 179,999 | 17,094 RSUs outstanding (as of Dec 31, 2023) | Per Inogen program | Not specified for directors |
- LMNR program design: equity equals 50% of total annual director compensation; balance in cash; equity awards require minimum one-year vesting under the 2022 Omnibus Incentive Plan .
- No options issued to LMNR directors; none outstanding .
- Clawback policy at LMNR applies to executives; director equity is time-based and not performance-conditioned .
Other Directorships & Interlocks
| Network Link | Overlap with LMNR Stakeholders | Potential Conflict |
|---|---|---|
| Inogen (medical technology), MKS Instruments (semiconductor equipment) | Different industries from LMNR’s agriculture operations | None disclosed; Board notes no relationships requiring Item 404 disclosure |
| Nuburu (laser tech) prior service | Technology sector | None disclosed |
Expertise & Qualifications
- CPA; audit committee financial expert experience (Audit Chair at Nuburu; Audit Chair at MKSI) .
- Deep finance and accounting background (Harvard CFO, Draper CAO/VP Finance) .
- Sustainability orientation highlighted by LMNR (Board ESG commitment) .
- Board leadership roles externally (Inogen Chairperson) .
Equity Ownership
| Metric | Value |
|---|---|
| Common shares beneficially owned | 12,445 (includes 4,413 restricted shares vesting Mar 26, 2025; voting/dividend rights on those shares) |
| Ownership as % of outstanding | Less than 1% (Company classification) |
| Shares outstanding (common, as of Feb 12, 2025) | 18,045,169 |
| Hedging/Pledging policy | Hedging prohibited for Pre-Clearance Persons; pledging/margin requires prior written approval |
| Director ownership guideline | $150,000 of common stock value required for non-employee directors |
Governance Assessment
- Strengths: Independent director; chairs two key committees (Compensation; Nominating & Corporate Governance) ; strong committee engagement (Compensation 7 meetings, 95% attendance; Audit 4 meetings, 100% overall committee attendance) ; board-level independence affirmed ; director ownership guideline in place and anti-hedging/limited pledging controls ; no related-party transactions in FY 2024 and no family relationships disclosed .
- Compensation alignment: LMNR increased director equity and cash retainer to market levels based on independent consultant (Pearl Meyer), with equity at 50% of total; one-year vesting supports alignment without short-termism .
- External roles: Audit chair at MKSI and chair at Inogen bring governance and financial rigor; industries distinct from LMNR’s agriculture reduce conflict risk .
- RED FLAGS: None disclosed for related-party transactions; no hedging by policy; no director option repricing; Section 16 filings timely for FY 2024 .
- Watch items: Time commitments across multiple boards may warrant monitoring, though no attendance concerns disclosed at LMNR .
Overall signal: Mora’s financial expertise, committee leadership, and clean related-party profile support board effectiveness and investor confidence, with clear ownership and anti-hedging policies reinforcing alignment .
